NLRP3 and neoplasm: Pharmacological inhibition of NLRP3 inflammasome in HNSCC mouse models significantly reduces the IL-1β production, which reduces MDSCs, regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) but increases CD4 and CD8 T cells in tumors to improve anti-tumor immunity (86).